Gabrielle Masson

Madison

Senior Editor at Fierce Biotech

Editor @FierceBiotech | As read in Lily Poetry Review & Eunoia Review

Featured in: Favicon

fiercebiotech.com Favicon

beckershospitalreview.com Favicon

fiercepharma.com Favicon

beckersasc.com Favicon

beckersspine.com Favicon

beckersdental.com Favicon

ramaonhealthcare.com Favicon

newsbreak.com Favicon

ourcommunitynow.com Favicon

substack.com + 3 more

Articles

Inside ASCO 2025: Big data drops and a towering campaign

2 days ago | fiercepharma.com | Ayla Ellison |Angus Liu |Gabrielle Masson |Zoey Becker

Each year, the American Society of Clinical Oncology annual meeting brings together the biggest names and brightest minds in cancer research, and this year was no exception. In this episode of "The Top Line," Fierce reporters take you inside the action at ASCO 2025. Zoey Becker shares the story behind Johnson & Johnson’s dramatic “Breathtaking” campaign, staged on the 99th floor of Chicago’s Willis Tower.
ASCO: Bicara ties antibody to 46% 2-year survival rate for head and neck cancer subset

6 days ago | fiercebiotech.com | Gabrielle Masson

Bicara Therapeutics has unveiled updated data for its bifunctional antibody paired with Keytruda in head and neck squamous cell carcinoma (HNSCC), including a first look at overall survival (OS) data for HPV-negative patients, as the biotech enrolls for a pivotal trial in the indication.
ASCO: Kite’s CAR-T passes lymphoma safety trial with flying colors

1 week ago | fiercebiotech.com | Gabrielle Masson

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) occurring in patients with advanced B-cell lymphoma (BCL). The therapy was also tied to a complete response (CR) rate of 78% for patients receiving the highest cell therapy dose.
ASCO: Immatics PRAME cell therapy tied to 56% response rate in melanoma study

1 week ago | fiercebiotech.com | Gabrielle Masson

Immatics’ cell therapy has been linked to a 56% objective response rate (ORR) among 32 heavily pretreated patients with metastatic melanoma. The biotech previously shared progression-free survival (PFS) data for the preferentially expressed antigen in melanoma (PRAME) cell therapy known as IMA203, recording a median PFS of six months.
Biopharma briefing: Q1 trends, gene therapy updates and ASCO preview

1 week ago | fiercepharma.com | Ayla Ellison |Eric Sagonowsky |Kevin Dunleavy |Gabrielle Masson

Despite the long holiday weekend, news in biopharma never slows down. In this week’s episode of "The Top Line," the Fierce team breaks down some of the biggest stories from the past week. On the pharma side, Eric Sagonowsky and Kevin Dunleavy examine Big Pharma’s first-quarter 2025 performance. While most of the top 25 companies are still delivering strong sales growth despite emerging uncertainties in Washington, D.C., a few major players are starting to see a slowdown.
‘Hanging on by our fingernails’: Stealth CEO questions efficiency behind FDA rejection of rare disease drug

1 week ago | fiercebiotech.com | Gabrielle Masson

After communicating with the FDA about font sizes for potential packaging on its investigational injection, Stealth Biotherapeutics’ CEO thought approval for the ultra-rare genetic disease treatment was imminent. “It’s yet another delay after an already missed PDUFA date and an already extended PDUFA date and a really long priority review,” Stealth CEO Reenie McCarthy told Fierce Biotech.
Keros culls PAH asset, prompting layoffs for 70 workers

1 week ago | fiercebiotech.com | Gabrielle Masson

Keros Therapeutics is ending development of a phase 2 candidate designed to treat high blood pressure in the lungs, a move that has triggered layoffs for 45% of the biotech’s team. The Massachusetts company pulled the plug on a related midphase trial—dubbed Tropos—back in January after observing several safety signals.
5 people charged in $600K insider trading scheme tied to Novartis’ Chinook acquisition

1 week ago | fiercebiotech.com | Gabrielle Masson

Rouzbeh “Ross” Haghighat served as a Chinook board member up until the 2023 acquisition. Now, he’s being charged with securities fraud, 16 counts of insider trading, and two counts of conspiracy related to his time there, according to a May 23 release from the U.S. Department of Justice. Haghighat was previously charged with one count of conspiracy to commit insider trading, according to the release.
Biogen maps out $1B biobucks deal with RNAi-focused City Therapeutics

1 week ago | fiercebiotech.com | Gabrielle Masson

Big Biotech Biogen is venturing into the city, paying $16 million in cash to partner up with an RNAi company to build next-gen central nervous system drugs. The research pact—inked with recently emerged City Therapeutics—includes a $30 million investment from Biogen in exchange for a convertible note for the private biotech, representing a minority equity interest in City once converted, according to a May 27 release.
Biotech incubated by TCG Labs inks $210M deal for EpimAb’s T-cell engager

1 week ago | fiercebiotech.com | Gabrielle Masson

TCG Labs Soleil’s Juri Biosciences is offering EpimAb Biotherapeutics up to $210 million biobucks for exclusive licensing rights to the China biotech’s T-cell engager designed to treat metastatic prostate cancer. The global pact centers on EpimAb’s early-stage asset made to target kallikrein-related peptidase 2 (KLK2) and CD3, according to a May 27 release.